COGNITION THERAPEUTICS INC (CGTX) - Dilution Analysis

10-Q filing | 89.2M shares outstanding

10-K filing | 88.9M shares outstanding

S-3 filing: The company is filing an S-3 form to offer and sell up to $300,000,000 in the aggregate of common stock, preferred stock, debt securities, warrants, units, and subscription rights from time to time in one or more offerings.

10-Q filing | 88.3M shares outstanding

8-K filing: Cognition Therapeutics, Inc. entered into Securities Purchase Agreements to issue 14,700,000 shares of common stock at $2.05 per share in a registered direct offering, with gross proceeds of approximately $30.1 million. ($30.14M proceeds)

10-Q filing | 63.7M shares outstanding

10-Q filing | 61.8M shares outstanding

10-K filing | 32.2M shares outstanding

10-Q filing | 40.4M shares outstanding

10-Q filing | 40.1M shares outstanding

10-Q filing | 40.0M shares outstanding

10-K filing | 30.0M shares outstanding

8-K filing: Cognition Therapeutics, Inc. entered into an underwriting agreement to issue and sell 6,571,428 shares of common stock at $1.75 per share in a public offering, expecting net proceeds of approximately $10.4 million.

S-3 filing: This is an S-3 filing for the offer and resale of up to 6,030,532 shares of common stock by selling stockholders.

10-Q filing | 30.4M shares outstanding

10-Q filing | 29.6M shares outstanding

10-Q filing | 29.1M shares outstanding

10-K filing | 29.0M shares outstanding

8-K filing: Cognition Therapeutics, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, allowing the Company to sell up to $35,000,000 of shares of its common stock to Lincoln Park over a 36-month term. ($0.35M proceeds)

S-3 filing: The company may offer and sell up to $200,000,000 in the aggregate of common stock, preferred stock, debt securities, warrants, units, and subscription rights from time to time in one or more offerings. Additionally, the company is offering common stock in an at the market offering for up to $40,000,000.

8-K filing: Cognition Therapeutics, Inc. completed a public offering of 5,000,000 shares of common stock at $1.20 per share, with an option for the underwriters to purchase an additional 750,000 shares. ($5.4M proceeds)

10-Q filing | 23.0M shares outstanding

S-1 filing: This is an S-1 filing related to the offering of Offered Shares, including Firm Shares and Option Shares, by Cognition Therapeutics, Inc.

10-Q filing | 22.6M shares outstanding

10-Q filing | 22.4M shares outstanding

10-K filing | 0.5M shares outstanding

10-Q filing | 0.6M shares outstanding

S-1/A filing: Initial public offering of shares of common stock of Cognition Therapeutics, Inc.

S-1/A filing: This is an S-1/A filing for the initial public offering of common stock of Cognition Therapeutics, Inc.

S-1/A filing: This is an S-1/A filing for the initial public offering of common stock of Cognition Therapeutics, Inc.

S-1 filing: This is an initial public offering of common stock. The company intends to use the net proceeds to fund research and development of its product candidates and development programs and for working capital and other general corporate purposes.